Form 4: Baker Bros. Advisors Report Acquisition of Immunocore Holdings Share Options

Baker Bros. Advisors and related entities report the acquisition of non-qualified share options for Immunocore Holdings, granted to Ranjeev Krishana, an employee of Baker Bros. Advisors LP and a director of Immunocore.

Summary

• Baker Bros. Advisors LP, along with related entities and individuals, filed a Form 4 detailing changes in beneficial ownership of Immunocore Holdings plc (IMCR).
• The report concerns the grant of 12,925 non-qualified share options to Ranjeev Krishana, a full-time employee of Baker Bros. Advisors LP, who also serves as a director of Immunocore Holdings.
• These share options have a strike price of $46.05 and vest in equal monthly installments over three years, contingent on Ranjeev Krishana's continued service on the board.
• The options expire on May 27, 2035.
• The filing clarifies that while Ranjeev Krishana received the options, the Baker Bros. Funds have an indirect proportionate pecuniary interest in these securities.
• Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest due to their ownership interests in the general partners of the Funds.
• Baker Bros. Advisors has voting and dispositive power over the share options and any ordinary shares acquired through their exercise.
• The filing includes disclaimers of beneficial ownership by Julian C. Baker, Felix J. Baker, the Adviser GP, and the Adviser, except to the extent of their pecuniary interest.

Sentiment

Score: 6

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. The grant of share options is a common practice and doesn't inherently suggest positive or negative implications for the company's performance.

Positives

• The acquisition of share options could align the interests of Baker Bros. Advisors with the long-term success of Immunocore Holdings.
• The vesting schedule encourages continued service and commitment from Ranjeev Krishana.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Comparison to Industry Standards

• The vesting schedule and terms of the share options appear typical for equity compensation plans in the biotechnology industry.
• Similar grants are often seen in companies like Amgen, Gilead, and Regeneron to incentivize key personnel and align their interests with shareholders.

Stakeholder Impact

• The grant of share options may have a minor positive impact on employee morale and retention.
• Shareholders may view the grant as a way to align management's interests with the company's long-term performance.

Key Dates